Scale-up Cealus Health starts key study on microbiome product
June 28, 2021Amsterdam UMC scale-up company Caelus Health has reached an important milestone.
Caelus Health recently started a key clinical trial in individuals suffering from Metabolic Syndrome or pre-diabetes; these individuals are at risk of developing Type 2 diabetes.
The microbiome product based on a single micro-organism (named A. soehngenii) may delay or even prevent the onset of diabetes. The trial is a final step in the development and registration of this product as a food supplement following successful completion of the previous study.
Caelus Health was established in close cooperation with Wageningen University.
More news
UvA spin-off Eddytec wins Women TechEU Grant
This €75k funding will help validate their business model and accelerate their go-to-market strategy. Eddytec’s technology aims to revolutionize maintenance and quality control processes for aircraft components, making them faster, easier, and more cost-effective.
News
NWO Take-off Approvals Announced for VU and UvA
The fall 2024 round of the NWO Take-off Grant has brought exciting news for Amsterdam’s academic community. Four innovative projects have been selected, with two from the Vrije Universiteit Amsterdam (VU) and two from the Universiteit van Amsterdam (UvA). The Take-off grant empowers academics to explore the feasibility and commercial potential of their science-based ideas, […]
News
Highly impactful Amsterdam stroke innovation now reaches even more patients
Ten years ago, a groundbreaking medical innovation made it possible to remove a blood clot from stroke patients using a catheter procedure. The health benefits for patients after this procedure are often much greater than with other treatments. Thanks to the collaboration with Amsterdam UMC, this treatment is now also being performed at the Noordwest Ziekenhuisgroep in Alkmaar.
News